Evidence map›Paper›PMID 27206763›Full record

ReviewJournal of nephrology2017

Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know.

Giovanni Piotti, Elena Cremaschi, Umberto Maggiore

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Tacrolimus-why pharmacokinetics matter in the clinic.Frontiers in transplantation · 2023
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giovanni PiottiKidney and Pancreas Transplantation Unit, University Hospital of Parma, Parma, Italy. gpiotti@yahoo.it.
Elena CremaschiKidney and Pancreas Transplantation Unit, University Hospital of Parma, Parma, Italy.
Umberto MaggioreKidney and Pancreas Transplantation Unit, University Hospital of Parma, Parma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tacrolimus has long been the cornerstone of the immunosuppressive standard-of-care in kidney transplantation. Until recently, only an immediate-release formulation of tacrolimus was available in the clinic for twice-daily administration, a schedule that is known to hamper prescription adherence and contributes to the already significant tacrolimus interactions with other drugs and meals. In order to improve patient compliance, two once-daily prolonged-release formulations of tacrolimus have recently been developed and approved. Here we will analyze the main characteristics of these two prolonged-release formulations with the aim to provide practical clinical information for a fully aware drug prescription. Finally, the theoretical advantages of the prolonged-release formulations in terms of prescription adherence, blood level steadiness and drug efficacy and tolerability will be critically reviewed, in order to define the profile of renal recipients who may benefit most from the switch to once-daily tacrolimus.

Indexed as

Kidney TransplantationNephrologistsCytochrome P-450 CYP3ADelayed-Action PreparationsDrug CompoundingHumansImmunosuppressive AgentsMedication AdherenceTacrolimusCytochrome P-450 CYP3ADelayed-Action PreparationsImmunosuppressive AgentsTacrolimusExtended-releaseImmunosuppressionKidney transplantationOnce-dailyProlonged-releaseTacrolimus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.